IMPAACT Study Milestones

We've done a lot thanks to all of your hard work!



IMPAACT 2017/MOCHA

evaluating the safety, acceptability, tolerability, and pharmacokinetics of oral and long-acting injectable cabotegravir and long-acting injectable rilpivirine in children and adolescents with HIV

Enrolling
3 April 2019

First enrollment at Johns
Hopkins University Baltimore
NICHD, USA (5092)

describe the pharmacokinetics of rifapentine and isoniazid HIV-1-infected and HIV-1-uninfected in pregnant and postpartum women with latent TB infection

Closed to follow-up 10 April 2019

Five participating sites: GHESKIO, KEMRI, Lilongwe, Siriraj, Harare Family Care

evaluating the pharmacokinetics and safety of delamanid for children with multidrug-resistant tuberculosis

Enrolling
19 February 2019

First enrollment at Byramjee Jeejeebhoy Medical College, India (31441)

evaluating oral preexposure prophylaxis for primary HIV prevention among pregnant and postpartum adolescents and young women

Enrolling, 4 March 2019 & Completed PK Component 6 June 2019

First enrollment at Seke North, Zimbabwe (30306)




study of the HIV reservoir in the central nervous system of perinatally-infected youth with neurocognitive impairment

Enrolling
6 February 2019

First enrollment at Jacobi Medical Center NICHD, USA (5013)

evaluating the pharmacokinetic and safety study of doravirine and a fixed dose combination of doravirine, lamivudine and tenofovir disoproxil fumarate adolescents with HIV

Enrolling 2 July 2018




First enrollment at Boston Medical Center, USA (5011)

IMPAACT 2010/VESTED

<u>V</u>irologic <u>E</u>fficacy and <u>S</u>afety of ART Combinations with <u>T</u>AF/TDF, <u>E</u>FV, and <u>D</u>TG

Completed accrual 8 February 2019



22 sites in Botswana, Brazil, India, South Africa, Tanzania, Thailand, Uganda, USA, and Zimbabwe

examine if a Health and Wellness Cognitive Behavioral Therapy and Medication Management for depression improves outcomes for HIV-infected youth

Completed accrual 5 March 2019

13 sites in the USA


assess the safety of VRC01 administered with ART and the effect of VRC01 on HIV-1 DNA concentrations in peripheral blood among HIV-1-infected infants

Enrolling 6 August 2018

First enrollment at HGNI, Brazil (5097)

IMPAACT P1026s

prospective pharmacokinetic study of selected ARV drugs currently used in the clinical care of HIV-infected pregnant women during pregnancy and postpartum



Enrolled over 1000 pregnant and postpartum women November 2018

